Noticias de ARGX_US
Noticias del mercado
Últimas noticias sobre ARGX_US — 378 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Argenx said it would discontinue its Phase 3 Unity study of Efgartigimod SC in adults with moderate-to-severe Sjögren’s disease, an autoimmune condition.
Argenx obtained, on October 8, 2026, the first clinical readout of FB102 following the acquisition of Forte Biosciences in August 2026, and this Phase 2 study met its primary endpoint versus placebo. The group indicated that these data support advancing the candidate into Phase 3 in celiac disease, a condition for which no drug is currently approved.<br><br>For a group that already commercializes the first approved FcRn receptor blocker and achieved revenue of $4.25 billion for the 2025 fiscal year (accounts published March 24, 2026), this result represents the first clinical test of an asset acquired externally and based on a distinct mechanism, CD122 blockade. At the end of September, Argenx presented new data on Vyvgart, its marketed product, at the AANEM and MGFA congresses.
Página 9 de 19